SCHEMBL5618489

SCHEMBL5618489

CNc1nccn2c(-c3cccc(NC(=O)CN4CCN(C)CC4)c3)cnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ DRD4 P21917 4/20 0.44
▸ DRD2 P14416 3/20 0.44
▸ DRD3 P35462 3/20 0.44
▸ JAK3 P52333 4/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ KIT P10721 1/20 0.44
▸ BCR P11274 1/20 0.44
▸ DDR1 Q08345 1/20 0.44
▸ GSK3B P49841 2/20 0.43
▸ DYRK1A Q13627 2/20 0.43
▸ JAK2 O60674 1/20 0.43
▸ TTK P33981 1/20 0.42
▸ BRAF P15056 1/20 0.42
▸ MET P08581 1/20 0.42
▸ ALK Q9UM73 1/20 0.42
▸ FGFR3 P22607 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5618376 0.93 JAK3 (0.51) EGFRALDH1A1DRD4DRD2DRD3
SCHEMBL5618369 0.90 JAK3 (0.54) EGFRALDH1A1DRD4DRD2DRD3
SCHEMBL5618277 0.90 JAK3 (0.45) DRD4DRD2DRD3JAK3JAK2
SCHEMBL5617999 0.89 TTK (0.53) ALDH1A1JAK2TTKKDR
SCHEMBL5416134 0.82 FYN (0.54) DYRK1ATTKBRAF
SCHEMBL5618443 0.81 TTK (0.55) ALDH1A1TTK
SCHEMBL5418767 0.81 MEN1 (0.47) EGFRABL1BCRTTKBRAF
SCHEMBL5405188 0.79 CHRNA7 (0.47) DRD4DRD2DRD3TTKBRAF
SCHEMBL5618973 0.79 TTK (0.47) ALDH1A1ABL1KITBCRDDR1
SCHEMBL5618784 0.79 TTK (0.52) ALDH1A1TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 EGFR 440/4885ALDH1A1 2826/4885DRD4 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback